{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-061473","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.236621+00:00","generated_at":"2026-06-05T01:59:57.284260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Neumora reports Q4 2023 net loss of $108.7M; cash $463.8M into 2026","bullets":["Net loss Q4 2023: $108.7M vs $28.1M in Q4 2022; full year net loss $235.9M vs $130.9M.","Cash, cash equivalents and marketable securities $463.8M as of Dec 31, 2023; expected to fund operations into 2026.","R&D expenses Q4 2023: $38.9M, up from $23.5M, driven by navacaprant Phase 3 startup and IPR&D costs.","Topline Phase 3 KOASTAL-1 data for navacaprant in MDD expected H2 2024; KOASTAL-2/3 data in H1 2025.","Phase 1 data for NMRA-266 (M4 PAM) in healthy adults expected mid-2024; Phase 1b in schizophrenia planned H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-061473","json":"https://secwatch.observer/filing/0001193125-24-061473.json","markdown":"https://secwatch.observer/filing/0001193125-24-061473.md","text":"https://secwatch.observer/filing/0001193125-24-061473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/0001193125-24-061473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/d803910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:59:57.284260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c030f3cb3f1e046537f9279214d370636374ca44","claim":"Neumora Therapeutics, Inc. reported financial results for fiscal year ended December 31, 2023.","evidence_excerpt":"On March 7, 2024, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/0001193125-24-061473-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}